Kristen Zakian1,
Jing Qi2, Yuman Fong3, Leonard Saltz4,
Michael D'Angelica3, Nancy Kemeny4, Mithat Gonen5,
Jinru Shia6, Amita Shukla-Dave1, Kinh Gian Do7,
William Jarnagin3, Lawrence Schwartz2, Jason A.
Koutcher1
1Medical
Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States;
2Columbia University College of Physicians and Surgeons, New York,
NY, United States; 3Surgery, Memorial Sloan-Kettering Cancer
Center, New York, NY, United States; 4Medicine, Memorial
Sloan-Kettering Cancer Center, New York, NY, United States; 5Epidemiology
and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY,
United States; 6Pathology, Memorial Sloan-Kettering Cancer Center,
New York, NY, United States; 7Radiology, Memorial Sloan-Kettering
Cancer Center, New York, NY, United States
Chemotherapy for colorectal cancer has been implicated in hepatic changes including steatosis. In serial proton magnetic resonance spectroscopy (MRS) studies in patients with colorectal cancer, we measured hepatic lipids prior to chemotherapy, after 6 weeks and after 24 weeks of treatment. Six of 27 patients (23%) converted from non-steatotic to steatotic after 24 weeks of chemotherapy. Patients whose lipids increased significantly after 6 weeks of chemotherapy were likely to complete chemotherapy with elevated lipids. Proton MRS provides the oncologist with a window on hepatic lipids during chemotherapy and gives an early indication of lipid levels at the end of treatment.
Keywords